Consensus of Experts on the Treatment of Sexual Dysfunction after Surgery for Prostate Cancer in Taiwan.
Yu ChenHong-Chiang ChangWilliam J HuangChii-Jye WangThomas I-Sheng HwangChun-Hou LiaoChia-Chu LiuSee-Tong PangEric Yi-Hsiu HuangChih-Wei TsaoKuo-Chiang ChenShih-Ping LiuChao-Yuan HuangCheng-Hsing HsiehBang-Ping JiannPublished in: Journal of clinical medicine (2023)
According to the Taiwan Cancer Report, in 2018, prostate cancer was one of the top five cancers reported in men. Each year, many patients with prostate cancer undergo radical prostatectomy (RP) therapy. One of the most common RP complications is erectile dysfunction (ED). Although consensus guidelines for the management of sexual dysfunction after prostate cancer surgery have been developed for many Western and Asian countries, no such clinical practice guidelines have been developed for Taiwan. The consensus opinions expressed in this article were discussed by numerous experienced physicians in Taiwan, based on both existing international guidelines and their individual experiences with clinical trials and providing advice to clinical physicians on how to inform patients of the risk of ED prior to surgery. This review also discusses how recovery and rehabilitation may be affected by socioeconomic status, the existence of an intimate relationship, comorbidities, or the need for cancer adjuvant therapy and how to determine rehabilitation goals and provide appropriate treatments to assist in the recovery of both short- and long-term sexual function.
Keyphrases
- prostate cancer
- radical prostatectomy
- clinical practice
- clinical trial
- emergency department
- minimally invasive
- primary care
- papillary thyroid
- end stage renal disease
- mental health
- coronary artery bypass
- oxidative stress
- newly diagnosed
- chronic kidney disease
- randomized controlled trial
- public health
- stem cells
- risk factors
- prognostic factors
- peritoneal dialysis
- bone marrow
- acute coronary syndrome
- percutaneous coronary intervention
- coronary artery disease
- mesenchymal stem cells
- phase ii
- middle aged